TIDMIMM
RNS Number : 9046B
Immupharma PLC
26 September 2018
26 SEPTEMBER 2018
ImmuPharma PLC
("ImmuPharma" or the "Company")
INTERIM RESULTS ANNOUNCEMENT
for the six months ended 30 June 2018
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is pleased to
announce its interim results for the six months ended 30 June 2018
(the "Period").
Key Highlights
Lupuzor(TM)
-- Lupuzor(TM) demonstrated a superior response rate over
placebo (52.5% vs 44.6% "responders") in the primary analysis on
the Full Analysis Set of all 202 patients. However, due to the high
response rate in the placebo group, this superior response did not
allow statistical significance to be reached (p = 0.2631) and the
trial's primary end point was not met.
-- Across the whole study population, in those patients who had
anti-dsDNA autoantibodies, Lupuzor(TM) demonstrated a superior
response rate over placebo (61.5% vs 47.3%, p = 0.0967). Although
these results were not statistically significant, further data
analysis demonstrated that in the Europe cohort (130 patients)
Lupuzor(TM) plus standard of care showed statistically significant
reductions in disease activity compared to placebo plus standard of
care in 79 patients who were anti-dsDNA autoantibody positive
(71.1% vs 48.8%, p = 0.0218).
-- The study confirmed the outstanding safety profile of
Lupuzor(TM) , with no serious adverse events reported.
-- As announced on 7 September 2018, agreement signed with a
specialist provider to enter Lupuzor(TM) into a 'Managed Access
Programme'.
-- Open label extension study completes recruitment.
Other programs
-- Nucant (cancer) program - Clinical Development Collaboration with Incanthera Limited.
-- Peptide platform program / Ureka subsidiary - ImmuPharma to begin divestment process.
Financial Position
-- GBP10 million fundraising (before expenses) successfully completed in January 2018.
-- Stable financial performance over the Period, in line with market expectations
o Net assets of GBP9.9 million (31 December 2017: GBP3.6
million)
o Loss for the period of GBP4.1 million (H1 2017: GBP3.0
million)
-- Research and Development expenses of GBP2.5 million (H1 2017:
GBP2.3 million)
o Basic and diluted loss per share of 2.94p (H1 2017: 2.34p)
Appointment of new joint brokers
-- Stanford Capital Partners and SI Capital appointed as joint
brokers, working in conjunction with current NOMAD and broker,
Northland Capital Partners.
Commenting on the Interims and outlook Tim McCarthy, Chairman,
said:
"The Board is pleased to announce the interim results for the
six months ended 30 June 2018. It has been a busy period for the
Board following the announcement of the Phase III trial results for
Lupuzor in April 2018. We remain focused on delivering a business
strategy which provides the optimum route forward for ImmuPharma
and its shareholders, based on its current assets, resources and
knowhow. We were obviously disappointed with the outcome of the
Phase III trial results but are excited to be progressing the
Managed Access Programme with a new strategic partner, which allows
lupus patients early access to Lupuzor(TM) . In the medium term, we
remain focussed on achieving the full regulatory approval of
Lupuzor(TM) which we believe has the potential to be a ground
breaking drug for lupus patients with blockbuster potential in
commercial terms.
Our Nucant programme and Ureka subsidiary have been part of our
portfolio for a number of years. We are equally excited by the
potential of both. We believe the strategy we announced earlier
this month, together with a robust financial position, will create
enhanced value for shareholders going forward."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma PLC + 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Dimitri Dimitriou, Chief Executive
Officer
Tracy Weimar, Vice President, Operations
and Finance
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
Northland Capital Partners Limited,
Nomad & Joint Broker +44 (0) 20 3861 6625
David Hignell, Jamie Spotswood, Dugald
Carlean, Corporate Finance
Rob Rees, Corporate Broking
Stanford Capital Partners, Joint Broker
Patrick Claridge
Chris Coleman +44 (0) 20 3815 8880
SI Capital, Joint Broker
Nick Emerson +44 (0) 1483 413500
CHAIRMAN'S STATEMENT
INTERIM HIGHLIGHTS
The first half of 2018 saw the completion of our pivotal Phase
III trial for Lupuzor(TM) , our candidate for the treatment of
lupus. Top-line results were announced on 17 April 2018 with
further analysis provided on 29 May 2018. Following these results,
ImmuPharma has recently signed an agreement with a specialist
provider to distribute Lupuzor(TM) via a Managed Access Programme.
This will allow lupus patients early access to Lupuzor(TM) prior to
any regulatory filing.
ImmuPharma has, on 6 September 2018, signed a Heads of Terms on
a clinical development collaboration for the Nucant cancer
programme with Incanthera Limited, a specialist oncology
development company. Further, following an extensive review, it has
been decided that the Company's Ureka subsidiary which focuses on
peptide treatments for metabolic disorders is not part of the
ongoing strategy of ImmuPharma which is now fully focused on
utilising its resources to develop late stage assets. Consequently,
we are beginning the process of divesting Ureka.
In other developments, we were pleased to have completed a
successful fund raising of GBP10 million (before expenses) in
January 2018. The fund raising was supported by long term
shareholders and the addition of new institutional and private
investors.
Lupuzor(TM) Phase III results and next steps
The Phase III trial was a double-blind, randomised,
placebo-controlled trial. The study involved patients being dosed
for one year, receiving 0.2mg once per month subcutaneously. 293
patients were screened illustrating the demand from physicians for
a new, safe and effective treatment for lupus. Of these, the
required 202 patients were successfully recruited and randomised
(dosed). Patients participated in the trial in 7 countries across
28 sites.
The clinical trial was undertaken primarily by Simbec-Orion, an
international clinical research organisation, who specialises in
rare and orphan conditions and has previous direct experience in
lupus trials. This was a pivotal study designed to demonstrate the
safety and efficacy of Lupuzor(TM) .
Lupuzor(TM) demonstrated a superior response rate over placebo
(52.5% vs 44.6% "responders") in the primary analysis on the Full
Analysis Set of all 202 patients. However, due to the high response
rate in the placebo group, this superior response did not allow
statistical significance to be reached (p = 0.2631) and the trial's
primary end point was not met.
Across the whole study population, in those patients who had
anti-dsDNA autoantibodies, Lupuzor(TM) demonstrated a superior
response rate over placebo (61.5% vs 47.3%, p = 0.0967). Although
these results were not statistically significant, further data
analysis demonstrated that in the Europe cohort (130 patients)
Lupuzor(TM) plus standard of care showed statistically significant
reductions in disease activity compared to placebo plus standard of
care in 79 patients who were anti-dsDNA autoantibody positive
(71.1% vs 48.8%, p = 0.0218).
The study confirmed the outstanding safety profile of
Lupuzor(TM) , with no serious adverse events reported.
Scientific literature indicates that approximately 60% - 70% of
patients diagnosed for lupus are anti-dsDNA autoantibody positive.
These proportions were seen in the Europe cohort (60.8% of
patients) and could therefore be considered as representative of
the overall lupus population.
In those patients who were anti-dsDNA autoantibody negative,
there was almost no difference in disease activity reduction
between the active group and the comparator group. Anti-dsDNA
autoantibodies are a recognised biomarker for Systemic Lupus
Erythematosus.
This finding indicates that the activity of Lupuzor(TM) could be
correlated with the presence of anti-dsDNA autoantibodies in lupus
patients. ImmuPharma believes that predictive biomarkers, such as
anti-dsDNA autoantibodies, could allow identification of patients
that are more likely to respond positively to treatment with
Lupuzor(TM) .
Lupuzor(TM) next steps - Managed Access Program
ImmuPharma is planning to move forward with a Managed Access
Program for Lupuzor(TM) . Recognising that lupus is a disease with
significant unmet medical need and given the advanced level of
clinical trial investigation completed, ImmuPharma would like to
meet demand for access to Lupuzor(TM) by lupus patients who,
together with their physicians, request it.
Extension study
The Lupuzor(TM) extension study, which was announced on 18
January 2018, is continuing and recruitment is now complete with a
total of 62 patients eligible from the original Phase III trial. We
believe that this will provide more valuable information on the
potential efficacy and safety of Lupuzor(TM) . The study is
anticipated to report results in Q2 2019.
Nucant Platform
A number of options have been under review to develop the
Company's Nucant cancer programme, which has demonstrated promising
results in two Phase I trials (safety and dose-finding
studies).
In order to progress the programme, on 6 September 2018
ImmuPharma signed Heads of Terms on a clinical development
collaboration for the Nucant cancer programme, with Incanthera
Limited ("Incanthera"), a specialist oncology development
company.
Key highlights of the Heads of Terms are summarised below:
-- Incanthera, based on its positive due-diligence on the
Company's Nucant technology, will license in and take up the
continued clinical development of the Nucant cancer programme as an
integral part of its own cancer development portfolio.
-- As an integral part of the collaboration, upon signing the
Heads of Terms, ImmuPharma has invested GBP2m into Incanthera by
subscribing for 363,637 new ordinary Incanthera shares at a price
of GBP5.50 per share. This investment values Incanthera at a
pre-money valuation of approximately GBP10m and is consistent with
the most recent funding round that Incanthera completed in March
2018. Following this investment, ImmuPharma will have a circa 16%
shareholding in Incanthera.
-- ImmuPharma has granted Incanthera a period of exclusivity
until 31 December 2018, during which the Company and Incanthera
will finalise the terms of a Definitive Licence Agreement for the
Nucant technology. These terms are expected to include, but will
not be limited to the following:
o Incanthera will pay a licence payment to ImmuPharma of GBP1
million, with this payment to be made via the issuance of new
ordinary shares in Incanthera. This payment in shares is separate
and will be in addition to the shareholding which Immupharma
currently holds as described above;
o Incanthera will be responsible for all of the development
costs for the Nucant programme; and,
o All future commercialisation revenues will be shared equally
between the two companies.
Ureka - Divestment process
Ureka, ImmuPharma's wholly owned subsidiary, based in Bordeaux,
which is carrying out research into treatments for Type II diabetes
and NASH (Non-Alcoholic-Steato-Hepatitis) has recently demonstrated
success in recognised preclinical studies.
Following an extensive review by ImmuPharma's Board of
directors, it has been decided that Ureka, whilst having exciting
and innovative technologies, is not part of the ongoing strategy of
ImmuPharma, which is now fully focused on utilising its resources
to develop late stage assets.
As such, ImmuPharma, with its advisors, will now commence a
process of considering all opportunities to divest Ureka. The
intention is to allow ImmuPharma to divest Ureka, whilst still
retaining an interest in any future commercial success.
Financial Review
ImmuPharma's cash balance at 30 June 2018 was GBP9.02 million
(GBP2.73 million at 31 December 2017, GBP3.13 million at 30 June
2017). Basic and diluted loss per share were 2.94p and 2.94p
respectively (30 June 2017: 2.34p and 2.34p). In line with the
Company's current policy, no interim dividend is proposed.
Operating loss for the Period was GBP4.1 million (GBP3.2 million
for the six months ended 30 June 2017). Research and development
expenditure in the Period was GBP2.5 million (GBP2.3 million for
the six months ended 30 June 2017) reflecting primarily the
expenditure related to the Lupuzor(TM) Phase III clinical trial.
Administrative expenses were GBP1.0 million during the Period
(GBP0.8 million for the six months ended 30 June 2017). The share
based expense was GBP775k (GBP131k for the period ended 30 June
2017) which includes a reduction for the National Insurance
provision which was nil due to the decrease in share price from 31
December 2017 to 30 June 2018.
Given the stage of ImmuPharma's development, the fact that
losses have continued to be made is to be expected since there is
minimal revenue and business activity is concerned with significant
investment in the form of clinical development expenditure, in
addition to maintaining the infrastructure of the Company.
Current Activities and Outlook
The Board has been focused on delivering a business strategy
which provides the optimum route forward for ImmuPharma and its
shareholders, based on its current assets, resources and knowhow.
We are excited to be progressing the Managed Access Programme which
allows lupus patients early access to Lupuzor(TM) . In the medium
term, we remain focussed on achieving the full regulatory approval
of Lupuzor(TM) which we believe has the potential to be a ground
breaking drug for lupus patients with blockbuster potential in
commercial terms.
Our Nucant programme and Ureka subsidiary have been part of our
portfolio for a number of years. We are equally excited by the
potential of both. We believe the strategy we are pursuing with the
collaboration with Incanthera Limited for the Nucant and for
divestment of Ureka will create enhance value for shareholders
going forward.
The Board would like to thank its shareholders, both
longstanding and those who participated in the January 2018
fundraising, for their support as well as its staff, corporate and
scientific advisers including Simbec-Orion and the CNRS (Centre
Nationale de la Recherche Scientifique) for their continued
collaboration.
Tim McCarthy
Chairman
ImmuPharma PLC
CONSOLIDATED INCOME STATEMENT
FOR THE PERIODED 30 JUNE 2018
Note Unaudited Audited Unaudited
6 months Year 6 months
ended ended ended
30 June 31 December 30 June
2018 2017 2017
GBP GBP GBP
Continuing operations
Revenue 1 73,392 150,462 86,504
Research and development
expenses (2,455,490) (5,121,388) (2,345,815)
Administrative expenses (992,085) (1,520,356) (796,403)
Share based expense (775,135) (742,752) (131,237)
Operating loss (4,149,318) (7,234,034) (3,186,951)
Finance costs (29,425) (3,858) (375)
Finance income 6,077 240,447 153,915
Loss before taxation (4,172,666) (6,997,445) (3,033,411)
Tax 110,237 774,244 (485)
Loss for the period (4,062,429) (6,223,201) (3,033,896)
Attributable to:
Equity holders of the parent
company (4,062,429) (6,223,201) (3,033,896)
Loss per ordinary share
Basic and diluted 2 (2.94)p (4.75)p (2.34)p
ImmuPharma PLC
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIODED 30 JUNE 2018
Unaudited Audited Unaudited
6 months Year 6 months
ended ended 31 ended
30 June December 30 June
2018 2017 2017
GBP GBP GBP
Loss for the financial period (4,062,429) (6,223,201) (3,033,896)
Other comprehensive income
Items that may be reclassified
subsequently to profit or loss:
Exchange differences on translation
of foreign operations 29,459 (91,568) (56,133)
Total items that may be reclassified
subsequently to profit or loss 29,459 (91,568) (56,133)
Other comprehensive loss for
the period 29,459 (91,568) (56,133)
Total comprehensive loss for
the period (4,032,970) (6,314,769) (3,090,029)
ImmuPharma PLC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2018
Note Unaudited Audited Unaudited
30 June 31 December 30 June
2018 2017 2017
GBP GBP GBP
Non-current assets
Intangible assets 481,667 482,268 497,585
Property, plant and equipment 120,675 161,399 192,573
Total non-current assets 602,342 643,667 690,158
Current assets
Trade and other receivables 1,174,720 1,644,128 2,439,143
Derivative financial asset - - 943,861
Cash and cash equivalents 9,015,630 2,729,468 3,131,595
Total current assets 10,190,350 4,373,596 6,514,599
Current liabilities
Financial liabilities -
borrowings 138,214 142,393 119,430
Trade and other payables 737,035 929,569 473,867
Provisions - 57,517 33,162
Total current liabilities 875,249 1,129,479 626,459
Net current assets 9,315,101 3,244,117 5,888,140
Non-current liabilities
Financial liabilities -
borrowings 61,209 117,297 170,232
Provisions - 195,989 -
Net assets 9,856,234 3,574,498 6,480,066
EQUITY
Ordinary shares 13,946,744 13,252,299 13,252,298
Share premium 27,320,143 18,728,519 18,728,519
Merger reserve 106,148 106,148 106,148
Other reserves (1,902,921) (2,961,017) (3,316,753)
Retained earnings (29,613,880) (25,551,451) (22,362,146)
Total equity 9,856,234 3,574,498 6,408,066
ImmuPharma PLC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIODED 30 JUNE 2018
Other Other reserves Other
Merger reserves - - reserves Retained
reserve Acquisition Translation - Earnings
reserve Reserve Equity
shares
Share Share to be Total
capital premium issued equity
GBP GBP GBP GBP GBP GBP GBP GBP
At 1 January
2017 12,463,836 15,678,054 106,148 (3,541,203) (1,609.673) 1,777,131 (19.328.250) 5,546,043
Loss for the
financial
period - - - - - - (3,033,896) (3,033,896)
Exchange
differences
on
translation
of foreign
operations - - - - (56,133) - - (56,133)
New issue of
equity
capital 788,462 3,311,542 - - - - - 4,100,004
Cost of new
issue of
equity
capital - (261,077) - - - - - (261,077)
Share based
payments - - - - - 113,125 - 113,125
------------ ------------ ---------- ------------- --------------------- ----------- -------------- -------------
At 30 June
2017 13,252,298 18,728,519 106,148 (3,541,203) (1,665,806) 1,890,256 (22,362,146) 6,408,066
============ ============ ========== ============= ===================== =========== ============== =============
At 1 January
2017 12,463,836 15,678,054 106,148 (3,541,203) (1,609,673) 1,777,131 (19,328,250) 5,546,043
Loss for the
financial
year - - - - - - (6,223,201) (6,223,201)
Exchange
differences
on
translation
of foreign
operations - - - - (91,568) - - (91,568)
New issue of
equity
capital 788,463 3,311,542 - - - - - 4,100,005
Cost of new
issue of
equity
capital - (261,077) - - - - - (261,077)
Share based
payments - - - - - 504,296 - 504,296
------------ ------------ ---------- ------------- --------------------- ----------- -------------- -------------
At 31
December
2017
& 1 January
2018 13,252,299 18,728,519 106,148 (3,541,203) (1,701,241) 2,281,427 (25,551,451) 3,574,498
Loss for the
financial
period - - - - - - (4,062,429) (4,062,429)
Exchange
differences
on
translation
of foreign
operations - - - - 29,459 - - 29,459
New issue of
equity
capital 694,445 9,305,555 - - - - - 10,000,000
Cost of new
issue of
equity
capital - (713,931) - - - - - (713,931)
Share based
payments - - - - - 1,028,637 - 1,028,637
At 30 June
2018 13,946,744 27,320,143 106,148 (3,541,203) (1,671,782) 3,310,064 (29,613,880) 9,856,234
============ ============ ========== ============= ===================== =========== ============== =============
Attributable
to:-
Equity
holders of
the
parent
company 13,946,744 27,320,143 106,148 (3,541,203) (1,671,782) 3,310,064 (29,613,880) 9,856,234
============ ============ ========== ============= ===================== =========== ============== =============
ImmuPharma PLC
CONSOLIDATED STATEMENT OF CASHFLOWS
FOR THE PERIODED 30 JUNE 2018
Note Unaudited Audited Unaudited
6 months Year 6 months
ended ended ended
30 June 31 December 30 June
2018 2017 2017
GBP GBP GBP
Cash flows from operating
activities
Cash used in operations 3 (3,150,500) (5,439,079) (3,200,329)
Tax 213,724 1,021,915 6,680
Interest paid (2,423) (3,858) (375)
Net cash used in operating
activities (2,939,199) (4,421,022) (3,194,024)
Investing activities
Purchase of property,
plant and equipment (7,946) (25,491) (1,595)
Interest received 6,077 772 170
Net cash used in investing
activities (1,869) (24,719) (1,425)
Financing activities
(Decrease)/increase in bank
overdraft (122) (290) (138)
Loan repayments (58,615) (114,386) (80,447)
Gross proceeds from issue
of new share capital 10,000,000 4,100,005 4,100,004
Settlements from sharing
agreement - 1,667,380 682,360
Share capital issue costs (713,931) (261,077) (261,077)
Net cash generated from financing
activities 9,227,332 5,391,632 4,440,702
Net increase in cash and
cash equivalents 6,286,264 945,891 1,245,253
Cash and cash equivalents
at start of period 2,729,468 1,876,718 1,876,718
Effects of exchange rates
on cash and
cash equivalents (102) (93,141) 9,624
Cash and cash equivalents
at end of period 9,015,630 2,729,468 3,131,595
ImmuPharma PLC
NOTES TO THE CONSOLIDATED INTERIM ACCOUNTS FOR THE PERIODED 30
JUNE 2018
1 ACCOUNTING POLICIES
Basis of preparation
The interim financial information in this report has been
prepared using accounting policies consistent with IFRS as adopted
by the European Union. IFRS is subject to amendment and
interpretation by the International Accounting Standards Board
(IASB) and the IFRS Interpretations Committee and there is an
ongoing process of review and endorsement by the European
Commission. The financial information has been prepared on the
basis of IFRS to be adopted by the European Union and applicable as
at 31 December 2018. The Group has chosen not to adopt IAS 34
"Interim Financial Statements" in preparing the interim financial
information.
The accounting policies applied are consistent with those that
were applied to the financial statements for the year ending 31
December 2017, with the exception of IFRS 9 "Financial Instruments"
and IFRS 15 "Revenue from Contracts with Customers" which are new
standards applicable mandatory for the year ended 31 December 2018.
These new standards will not have a material impact on the
financial statements.
Non-Statutory accounts
The financial information set out in this interim report does
not constitute the Group's statutory accounts, within the meaning
of Section 434 of the Companies Act 2006. The statutory accounts
for the year ended 31 December 2017 have been filed with Registrar
of Companies. The auditors reported on those accounts; their report
was unqualified, did not contain a statement under either Section
498 (2) or Section 498 (3) of the Companies Act 2006 and did not
include references to any matters to which the auditor drew
attention by way of emphasis. The financial information for the 6
months ended 30 June 2018 and 30 June 2017 is unaudited.
Copies of this statement will be available on the Company's
website - www.immupharma.com.
2 LOSS PER SHARE
Unaudited Audited Unaudited
6 months Year ended 6 months
ended 30 31 December ended
June 2018 2017 30 June
2017
GBP GBP GBP
Loss
Loss for the purposes of basic
and diluted loss per share
being net loss attributable
to equity shareholders (4,062,429) (6,223,201) (3,033,896)
Number of shares
Weighted average number of
ordinary shares for the purposes
of basic loss per share 138,201,316 130,902,857 129,517,245
Basic loss per share (2.94)p (4.75)p (2.34)p
Diluted loss per share (2.94)p (4.75)p (2.34)p
There is no difference between basic loss per share and diluted
loss per share as the share options and warrants are
anti-dilutive.
The ImmuPharma group has granted share options in respect of
shares to be issued.
3 CASH USED IN OPERATIONS
Unaudited Audited Unaudited
6 months Year ended 6 months
ended 31 December ended
30 June 2017 30 June
2018 2017
GBP GBP GBP
Operating loss (4,149,318) (7,234,034) (3,186,951)
Depreciation & amortisation 81,424 138,198 61,954
Share based payments 1,028,637 504,296 113,125
Decrease in trade & other
receivables 358,921 643,466 34,004
(Decrease)/increase in trade
& other payables (189,656) 143,378 (322,963)
(Decrease)/increase
in provisions (253,506) 238,456 18,112
Gain/(loss) on foreign
exchange (27,002) 127,161 82,390
Cash used in operations (3,150,500) (5,439,079) (3,200,329)
4 SUBSEQUENT EVENTS
On 7 September 2018, ImmuPharma announced that a Heads of
Terms agreement was signed with Incanthera Limited. Under
the Heads of Terms agreement, Incanthera Limited will license
in and take up the continued clinical development of the
Nucant cancer programme as an integral part of its own cancer
development portfolio. As part of the Heads of Terms, ImmuPharma
has invested GBP2 million into Incanthera Limited by subscribing
for 363,637 new ordinary Incanthera shares at a price of
GBP5.50 per share. Following this investment, ImmuPharma
will have approximately 16% shareholding in Incanthera Limited.
Under the Heads of Terms, ImmuPharma has granted Incanthera
Limited a period of exclusivity until 31 December 2018,
during which the two companies will finalise terms of a
Definitive License Agreement for the Nucant technology.
These terms are expected to include, but will not be limited
to Incanthera Limited paying a license payment to ImmuPharma
of GBP1 million, with this payment being made via the issuance
of new ordinary shares in Incanthera Limited. It is also
planned to include confirmation that Incanthera Limited
will be responsible for all of the development costs of
the Nucant programme and confirmation that all future commercialisation
revenues will be shared equally between the two companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IR UVOSRWUAKUAR
(END) Dow Jones Newswires
September 26, 2018 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024